Thyromazol

Thyromazol

  • $22.00



Manufacturer: Abdi Ibrahim, Turkey
Pharmaceutical name: Methimazole
Pack: 1 pack (100 tabs (5mg))
Thyromazol, commonly referred to as Methimazole, functions by inhibiting the production of thyroid hormones. It obstructs the synthesis of these hormones by preventing the oxidation of iodine and its ability to bond with tyrosine to create thyroxine and triiodothyronine (T3). Onset: 12-18 hours. Duration: 36-72 hours.
 
Thyromazol is swiftly absorbed from the gastrointestinal tract. Peak plasma levels occur after 1 hour. It easily crosses the placenta and is distributed into breast milk. The elimination half-life ranges from 5 to 13 hours.
 
Thyromazol should be taken with meals.
 
Thyromazol attaches to thyroid peroxidase, thereby hindering the conversion of iodide to iodine. Normally, thyroid peroxidase converts iodide to iodine (using hydrogen peroxide as a cofactor) and also facilitates the incorporation of the resulting iodine molecule onto the 3 and/or 5 positions of the phenolic rings of tyrosines present in thyroglobulin. Thyroglobulin is subsequently broken down to yield thyroxine (T4) and tri-iodothyronine (T3), the primary hormones synthesized by the thyroid gland. Thus, Methimazole effectively reduces the generation of new thyroid hormones.
 
Avoid taking Thyromazol alongside other medications known to induce agranulocytosis. Dosages of β-blockers, digoxin, warfarin, and theophylline may need to be adjusted in response to thyroid status changes. Co-administration may enhance the clearance of prednisolone and increase the risk of QT interval prolongation when using macrolides.
 
The side effects of Thyromazol include: allergic skin reactions, jaundice, nausea, vomiting, abdominal distress, loss of taste, joint pain, muscle pain, tingling sensations, headaches, drowsiness, peripheral nerve inflammation, dizziness, swelling of salivary glands, swollen lymph nodes, drug fever, lupus-like symptoms, periarteritis, low prothrombin levels, and hypothyroidism (after prolonged use). Potentially serious risks include blood disorders, particularly agranulocytosis and